Aleksandra Butrym1, Justyna Rybka, Dagmara Baczyńska2, Andrzej Tukiendorf3, Kazimierz Kuliczkowski, Grzegorz Mazur. 1. 2Department of Physiology, Wroclaw Medical University, Chałubinski 10 Str, 50-368 Wroclaw, Poland. 2. 3Department of Forensic Medicine, Molecular Techniques Unit, Wroclaw Medical University, Curie-Sklodowskiej 52 Str, 50-369 Wroclaw, Poland. 3. 4Department of Epidemiology, Cancer Center-Institute of Oncology, Wybrzeże Armii Krajowej 15, 44-101 Gliwice, Poland.
Abstract
AIM: Aberrant expression of microRNAs (miRs) has been proved to have a role in acute myeloid leukemias (AML), but there is no information on miR-331 in AML. MATERIALS & METHODS: miR-331 expression has been analyzed using reverse-transcription polymerase chain reaction (RT-PCR) in 95 bone marrow specimens from newly diagnosed AML patients in comparison with 20 healthy subjects. RESULTS: miR-331 was upregulated in AML patients and its expression seemed to influence remission achieving and death risk. The time of remission duration in patients with complete remission was longer in subjects with miR-331 downregulation after induction chemotherapy. CONCLUSION: we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AML patients.
AIM: Aberrant expression of microRNAs (miRs) has been proved to have a role in acute myeloid leukemias (AML), but there is no information on miR-331 in AML. MATERIALS & METHODS:miR-331 expression has been analyzed using reverse-transcription polymerase chain reaction (RT-PCR) in 95 bone marrow specimens from newly diagnosed AMLpatients in comparison with 20 healthy subjects. RESULTS:miR-331 was upregulated in AMLpatients and its expression seemed to influence remission achieving and death risk. The time of remission duration in patients with complete remission was longer in subjects with miR-331 downregulation after induction chemotherapy. CONCLUSION: we showed for the first time that miR-331 higher expression appears to be correlated with worse response to therapy and shorter survival of AMLpatients.
Authors: Aleksandra Butrym; Justyna Rybka; Dagmara Baczyńska; Andrzej Tukiendorf; Kazimierz Kuliczkowski; Grzegorz Mazur Journal: J Exp Clin Cancer Res Date: 2015-07-01
Authors: Aleksandra Butrym; Piotr Łacina; Kazimierz Kuliczkowski; Katarzyna Bogunia-Kubik; Grzegorz Mazur Journal: BMC Cancer Date: 2018-01-30 Impact factor: 4.430
Authors: Michael R Epis; Keith M Giles; Dianne J Beveridge; Kirsty L Richardson; Patrick A Candy; Lisa M Stuart; Jacqueline Bentel; Ronald J Cohen; Peter J Leedman Journal: Oncotarget Date: 2017-06-27